Scarica l'app Stockscreener
53.34
0.88%
-0.38
Precedente Chiudi:
$53.72
Aprire:
$53.63
Volume 24 ore:
26,942
Relative Volume:
0.04
Capitalizzazione di mercato:
$2.91B
Reddito:
$1.28B
Utile/perdita netta:
$-222.15M
Rapporto P/E:
-13.04
EPS:
-4.09
Flusso di cassa netto:
$145.52M
1 W Prestazione:
+7.44%
1M Prestazione:
+26.83%
6M Prestazione:
+12.78%
1 anno Prestazione:
+15.65%
Intervallo 1D:
$53.05
$53.98
Intervallo di 1 settimana:
$49.77
$54.72
Portata 52W:
$32.48
$57.35
Livanova Plc Stock (LIVN) Company Profile
Nome
Livanova Plc
Settore
Industria
Telefono
4402033250662
Indirizzo
20 EASTBOURNE TERRACE, LONDON
Confronta LIVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LIVN
Livanova Plc
|
53.32 | 2.93B | 1.28B | -222.15M | 145.52M | -4.09 |
|
ABT
Abbott Laboratories
|
131.64 | 229.31B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.08 | 152.87B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
382.36 | 146.01B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.83 | 119.18B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.68 | 45.95B | 5.69B | 1.41B | 577.90M | 6.95 |
Livanova Plc Stock (LIVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-20 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-10-04 | Iniziato | Goldman | Buy |
| 2024-09-17 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-03-20 | Reiterato | Needham | Buy |
| 2024-02-20 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Hold |
| 2023-07-19 | Iniziato | Robert W. Baird | Neutral |
| 2023-04-14 | Iniziato | Mizuho | Neutral |
| 2022-12-21 | Iniziato | Barclays | Equal Weight |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-02-24 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-03 | Iniziato | Goldman | Buy |
| 2021-08-20 | Reiterato | Needham | Buy |
| 2021-07-20 | Aggiornamento | Needham | Hold → Buy |
| 2021-03-03 | Downgrade | Berenberg | Buy → Hold |
| 2021-01-05 | Downgrade | Needham | Buy → Hold |
| 2020-09-02 | Iniziato | Robert W. Baird | Outperform |
| 2020-06-26 | Reiterato | Needham | Buy |
| 2019-10-30 | Reiterato | Needham | Buy |
| 2019-02-28 | Reiterato | Needham | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-08-02 | Reiterato | Needham | Buy |
| 2018-06-08 | Iniziato | Stifel | Buy |
| 2018-05-31 | Reiterato | Needham | Buy |
| 2018-02-28 | Reiterato | Needham | Buy |
Mostra tutto
Livanova Plc Borsa (LIVN) Ultime notizie
LivaNova’s Essenz perfusion system launches in China - Investing.com
LivaNova Launches Essenz Perfusion System in China - Eagle-Tribune
Should value investors consider LivaNova PLCJuly 2025 News Drivers & Low Risk Profit Maximizing Plans - thegnnews.com
Optimistic Investors Push LivaNova PLC (NASDAQ:LIVN) Shares Up 28% But Growth Is Lacking - simplywall.st
Bollinger Band Squeeze Points to Volatility in LivaNova PLCJuly 2025 News Drivers & Low Volatility Stock Suggestions - beatles.ru
What earnings revisions data tells us about LivaNova PLCMarket Volume Summary & AI Driven Stock Movement Reports - Newser
LivaNova PLC Enters Reversal Setup in Weekly ChartsJuly 2025 Technicals & Capital Protection Trade Alerts - beatles.ru
Sentiment analysis tools applied to LivaNova PLCPortfolio Value Summary & Fast Exit and Entry Strategy Plans - Newser
Why LivaNova (LIVN) Is Up 12.0% After Strong Q2 Results and Raised 2025 Revenue Guidance - simplywall.st
LivaNova PLC stock trend forecast2025 Price Targets & Long-Term Capital Growth Strategies - Newser
Machine Learning Models Forecast LivaNova PLC UptickWeekly Trend Report & Low Risk Entry Point Guides - sundaytimes.kr
Visual trend scoring systems applied to LivaNova PLC [Quarterly Trade Review]Free Risk Managed Investment Strategies - Newser
Chart based exit strategy for LivaNova PLCFree Capital Preserving Trade Plan Templates - Newser
Single-Chamber Pacemaker Market to Reach $2.77 Billion by 2031, - openPR.com
What recovery options are there for LivaNova PLCRisk/Reward Optimization Entry Point Analysis - Newser
LivaNova (LIVN) Is Up 18.7% After Strong Q2 Results and Raised 2025 Guidance – What's Changed - simplywall.st
Jefferies Reaffirms ‘Buy’ Rating on LivaNova PLC (LIVN) with $79 PT - MSN
How hedge fund analytics apply to LivaNova PLC stockAI Intraday Market Movement Prediction Tool - Newser
LivaNova PLC (NASDAQ:LIVN) Receives Average Recommendation of “Buy” from Analysts - Defense World
Can machine learning forecast LivaNova PLC recoveryFree Trade Ready Stock Watch for Short Term - Newser
LivaNova (NASDAQ:LIVN) Upgraded by Wall Street Zen to “Strong-Buy” Rating - Defense World
LivaNova PLC Company Revenue and Profit Trends: A Deep DiveSmart Risk Strategy with Entry Optimization - Newser
Real time scanner hits for LivaNova PLC explainedInvestment Position Summary with Timeframe Forecast - Newser
LivaNova PLC Reports Strong Q2 Earnings and Raised Guidance - The Globe and Mail
LivaNova (LIVN) Is Up 18.0% After Raising 2025 Outlook and Advancing Core Technology Platforms - simplywall.st
LivaNova PLC (NASDAQ:LIVN) Q2 2025 Earnings Call Transcript - Insider Monkey
Goldman Sachs raises Livanova stock price target to $168 on strong 2Q25 - Investing.com Nigeria
LivaNova Reports Strong Q2 2025 Revenue Growth, Raises Full-Year Guidance - AInvest
LivaNova raises 2025 organic growth outlook to 9%-10% with upgraded guidance for cardiopulmonary and epilepsy - MSN
Livanova stock price target raised to $65 from $55 at Mizuho - Investing.com Canada
LIVN Stock Price and Chart — NASDAQ:LIVN - TradingView
LivaNova Q2 2025 revenue increased 10.7% to USD 352.5M - Medical Buyer
Decoding LivaNova PLC (LIVN): A Strategic SWOT Insight - GuruFocus
LivaNova: Q2 Earnings Snapshot - Connecticut Post
LivaNova PLC Reports Strong Q2 2025 Results - TipRanks
LivaNova PLC (LIVN): Accelerating Growth in Neuromodulation and Cardiopulmonary Markets - AInvest
LivaNova Earnings: Strength in Cardiopulmonary Fuels Strong Second Quarter - Morningstar
LivaNova Has Found New Opportunities for Innovation in Its Strongholds - Morningstar
LivaNova Q2 2025 Earnings Call Transcript - MarketBeat
Transcript : LivaNova PLC, Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
LivaNova stock rises before hours on Q2 beats, raised guidance - MassDevice
LivaNova PLC reports results for the quarter ended June 30Earnings Summary - TradingView
LivaNova Exceeds Q2 Earnings Expectations with Robust GrowthNews and Statistics - IndexBox
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates - Yahoo Finance
LivaNova's Outperformance and Strategic Momentum in 2025: Why Revenue, Margin Expansion, and Clinical Innovation Justify a Buy Now Position in Medical Tech - AInvest
LIVN Forecasts Higher Revenue Growth for 2025 - GuruFocus
LivaNova Q2 Adjusted Earnings, Revenue Rise; Raises 2025 Adjusted Earnings Guidance - MarketScreener
LivaNova PLC Q2 2025 Earnings: EPS of $1.05 Beats Estimate, Reve - GuruFocus
LivaNova PLC earnings beat by $0.18, revenue topped estimates - Investing.com
LivaNova results exceed second-quarter expectations - Investing.com India
LivaNova's Strategic Momentum and Clinical Innovation: A Catalyst for Sustained Growth in 2025 - AInvest
Livanova Plc Azioni (LIVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Livanova Plc Azioni (LIVN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bianchi Francesco | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
3,416 |
0 |
10,938 |
| SCHERMERHORN TODD C | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
3,416 |
0 |
9,473 |
| KOZY WILLIAM A | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
4,840 |
0 |
33,148 |
| Barry James Christopher | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
3,416 |
0 |
4,772 |
| Story Brooke | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
3,416 |
0 |
6,892 |
| Enxing Seng Stacy | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
3,416 |
0 |
12,161 |
| WILVER PETER M | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
3,416 |
0 |
7,148 |
| Tezel Ahmet | Chief Innovation Officer |
Jun 15 '25 |
Option Exercise |
0.00 |
2,967 |
0 |
2,967 |
| Bolton Stephanie | President, Global Epilepsy |
Mar 30 '25 |
Option Exercise |
0.00 |
6,024 |
0 |
15,586 |
| Makatsaria Vladimir | Chief Executive Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
9,330 |
0 |
9,330 |
0.07%
0.41%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):